The therapy, Awiqli (insulin icodec), is intended for diabetic adults and is waiting on FDA approval for Type 1 and Type 2 diabetes. A phase 3 trial comparing the drug candidate to Novo Nordisk’s FDA-approved daily insulin product linked Awiqli to higher rates of hypoglycemic episodes. The study focused on Type 1 diabetes.
After about six hours of discussion among FDA panel members, a majority agreed the drug’s benefits do not outweigh the risks for improving glycemic control in adults with Type 1 diabetes, adding that more data is needed. The committee did not vote on Type 2 diabetes.
“Novo Nordisk has confidence in the potential of investigational once-weekly basal insulin icodec for those living with diabetes who require basal insulin therapy,” a spokesperson told Becker’s. “We will continue to work closely with [the] FDA to identify the next steps needed to help provide this novel treatment option for adults living with diabetes.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
